 HOOKIPA Pharma Inc. HOOK, a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the U.S. Food and Drug Administration FDA has cleared its Investigational New Drug IND Application for HB-202. This IND allows HOOKIPA to initiate an additional arm in its Phase 12 clinical trial for HB-201 NCT04180215 for the treatment of Human Papillomavirus 16-positive HPV 16 cancers. With the IND clearance of HB-202, HOOKIPA will be able to examine not only the safety and efficacy of HB-201 alone but also HB-201 in combination with HB-202 as an alternating two-vector therapy. 